How to deal with adverse reactions of Tarlatamab-Imdelltra

Tarlatamab-Imdelltra, as an immune bispecific antibody drug, has shown breakthrough efficacy in the treatment of extensive-stage small cell lung cancer (ES-SCLC), but like other immunotherapies, it may also cause a series of adverse reactions related to immune activation. The most common include cytokine release syndrome (CRS), neurotoxicity (ICANS), fever, fatigue, decreased appetite, and mild gastrointestinal discomfort. Proper identification and management of these side effects is a key link in ensuring the safety and efficacy of treatment.

Cytokine release syndrome is one of the most vigilant reactions during talatumumab treatment. CRS usually occurs during the first dose or early administration, and its symptoms include fever, hypotension, shortness of breath, and general fatigue. Mild CRS can be treated with symptomatic treatment such as antipyretics and intravenous fluid infusion support, while moderate to severe CRS may require suspension of medication and use of anti-IL-6 drugs such as Tocilizumab under the guidance of a doctor to control the immune response. During treatment, it is important to monitor body temperature, blood pressure, and oxygen saturation.

Another common immune-related adverse event is nervous system toxicity (ICANS), which manifests as confusion, speech impairment, or mild tremor. If a patient develops such symptoms, the medication should be discontinued immediately and a neurological evaluation should be performed. Doctors usually choose whether to use glucocorticoids, such as dexamethasone, to suppress the immune response based on the severity of symptoms, and then decide whether to resume treatment after the symptoms are relieved.

In addition, talatumumab may cause mild liver function abnormalities, cytopenias, or fatigue. Countermeasures include monitoring liver function indicators and blood routine. If abnormalities occur, the dose must be adjusted or medication delayed. In order to reduce the reaction of the first dose of infusion, doctors usually use a step-by-step administration method, that is, gradually increasing the dose during the first cycle to allow the body to adapt to immune stimulation, thereby reducing the risk of acute reactions.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html